Literature DB >> 21809999

Clinical performance of a human papillomavirus messenger RNA test (Aptima HPV Assay) on residual material from archived 3-year-old PreservCyt samples with low-grade squamous intraepithelial lesion.

Marianne Waldstrøm1, Dorthe Ornskov.   

Abstract

CONTEXT: Human papillomavirus (HPV) testing is widely used in the triage of women with a borderline smear result but the efficiency of testing women with low-grade squamous intraepithelial lesion (LSIL) is less clear, mainly because of lack of specificity. New HPV tests are emerging, which detect E6/E7messenger RNA (mRNA), and preliminary data suggest that they might have a higher specificity. However, mRNA is less stable than DNA, thus posing a challenge to the preservation abilities of the cell-collecting medium.
OBJECTIVE: To evaluate the clinical performance of an HPV mRNA assay on 3-year-old archived liquid-based samples, all with a diagnosis of LSIL.
DESIGN: The residual material from old archived PreservCyt samples from 442 women were tested with the Aptima HPV Assay, which detects E6/E7 mRNA from 14 high-risk HPV types. The samples had been stored at room temperature without any further handling.
RESULTS: Follow-up was available for 405 women, 67 of whom had histologic confirmed cervical intraepithelial neoplasia (CIN) 2+ and 31 with CIN 3+. The sensitivity and specificity for the mRNA assay was 92.5% and 38.2%, respectively, for detecting CIN 2+, and 93.9% and 35.5%, respectively, for detecting CIN 3+. When evaluating separately the performance of the test for women younger than 30 years and for women 30 years or older, the sensitivity was found to be similar in the 2 groups, but the specificity was significantly lower for the younger women.
CONCLUSION: Messenger RNA is well preserved in old archived PreservCyt samples. Triaging women with LSIL, using the Aptima HPV Assay, seems to be effective with a good sensitivity and a good specificity, especially for women 30 years or older.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21809999     DOI: 10.5858/2010-0411-OAR

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  E6/E7 proteins are potential markers for the screening and diagnosis of cervical pre-cancerous lesions and cervical cancer in a Chinese population.

Authors:  Wen-Jing Shi; Hao Liu; Dan Wu; Zhen-Hua Tang; Yu-Chen Shen; Lin Guo
Journal:  Oncol Lett       Date:  2017-09-14       Impact factor: 2.967

2.  A prospective study of women with ASCUS or LSIL pap smears at baseline and HPV E6/E7 mRNA positive: a 3-year follow-up.

Authors:  M T Bruno; M Ferrara; V Fava; G Barrasso; M M Panella
Journal:  Epidemiol Infect       Date:  2018-02-21       Impact factor: 4.434

3.  Presence of High-Risk HPV mRNA in Relation to Future High-Grade Lesions among High-Risk HPV DNA Positive Women with Minor Cytological Abnormalities.

Authors:  Hanna Johansson; Kaj Bjelkenkrantz; Lotten Darlin; Joakim Dilllner; Ola Forslund
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

Review 4.  Influence of Human Papillomavirus Infection on the Natural History of Cervical Intraepithelial Neoplasia 1: A Meta-Analysis.

Authors:  Mingzhu Liu; Xiaolong Yan; Mei Zhang; Xiaoju Li; Shugang Li; Mingxia Jing
Journal:  Biomed Res Int       Date:  2017-07-24       Impact factor: 3.411

5.  Analytic and Diagnostic Performances of Human Papillomavirus E6/E7 mRNA Test on up-to 11-Year-Old Liquid-Based Cervical Samples. A Biobank-Based Longitudinal Study.

Authors:  Roberta Zappacosta; Francesca Sablone; Lucia Pansa; Davide Buca; Danilo Buca; Sandra Rosini
Journal:  Int J Mol Sci       Date:  2017-07-11       Impact factor: 5.923

6.  Triage of HR-HPV positive women with minor cytological abnormalities: a comparison of mRNA testing, HPV DNA testing, and repeat cytology using a 4-year follow-up of a population-based study.

Authors:  Maria Persson; K Miriam Elfström; Sophia Brismar Wendel; Elisabete Weiderpass; Sonia Andersson
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.